Entity

Time filter

Source Type

Seoul, South Korea

Hong H.,Keimyung University | Hong H.,CHA Cancer Institute | Jang B.-C.,Keimyung University
International Journal of Molecular Medicine | Year: 2014

Hearing loss can be induced by multiple causes, including cochlear inflammation. Prednisone (PDN) is a well-known steroid clinically used in the treatment of hearing loss. In the present study, we investigated the inhibitory effects and the mechanisms of action of PDN on the expression of cyclooxygenase (COX)-2, an inflammatory enzyme involved in the production of prostaglandins (PGs), in House Ear Institute-Organ of Corti 1 (HEI-OC1) cells (a murine auditory cell line) treated with the inflammatory cytokine, interleukin (IL)-1β. The exposure of HEI-OC1 cells to IL-1β increased COX-2 protein and mRNA expression, COX-2 promoter-driven lucif-erase activity and COX-2 enzymatic activity [as indicated by the increased production of prostaglandin E2 (PGE2), a major COX-2 metabolite]. However, PDN markedly inhibited the IL-1β-induced COX-2 protein and mRNA expression, COX-2 promoter activity and PGE2 production in the HEI-OC1 cells without affecting COX-2 protein and mRNA stability. PDN further inhibited the IL-1β-induced activation of extracellular signal-regulated kinase (ERK)-1/2 and c-Jun N-terminal kinase (JNK)-1, but had no effect on the cytokine-induced activation of p38 MAPK and proteolysis of IκB-α, a nuclear factor-κB (NF- κB) inhibitory protein. PDN also partially suppressed the IL-1β-induced activation of activator protein (AP)-1 (but not that of NF-κB) promoter-driven luciferase activity. Of note, the inhibitory effects of PDN on the IL-1β-induced expression of COX-2 and the activation of ERK-1/2 and JNK-1 in the HEI-OC1 cells were significantly diminished by RU486, a glucocorti-coid receptor (GR) antagonist, suggesting that PDN exerts its inhibitory effects through GR. To the best of our knowledge, our study demonstrates for the first time that PDN inhibits the IL-1β-induced COX-2 expression and activity in HEI-OC1 cells by COX-2 transcriptional repression, which is partly associated with the inhibition of ERK-1/2, JNK-1 and AP-1 activation. Source


Park D.S.,CHA Medical University | Hong J.Y.,CHA Medical University | Hong Y.K.,CHA Medical University | Lee S.R.,CHA Medical University | And 5 more authors.
Urology | Year: 2013

Objective To investigate the relationship between prostate specific antigen (PSA) level and prostate volume (PV) according to age in a community-based population of Korean men enrolled in a large-scale screening program. Methods A total of 35,223 men who enrolled in the Korean Prostate Health Council Screening Program from January 2001 to December 2011 were included in this study. Patients with a serum PSA level of >10 ng/mL or younger than 40 years were excluded. We analyzed PSA level and PV as measured through transrectal ultrasonography according to stratified age cohorts. We used Pearson correlation and linear regression analysis according to age to describe the correlation between PSA level and PV. Results Mean PSA level and mean PV increased significantly with age (all P values <.001). Based on data from 5 age cohorts, mean PSA level increased about 0.3 ng/mL every 10 years and mean PV increased about 3 mL every 10 years. The slope of the linear regression between PSA level and PV was 4.582, and the slope of the linear regression increased with age. We derived equations relating PSA level and PV for the various age cohorts. Conclusion Based on a large-scale health screening program, we derived equations relating PSA level to PV according to age group. These data provide a baseline for the normal population by avoiding the interventional bias of urinary symptoms, in contrast to previous data derived from patients who visited hospitals because of prostate-related health concerns. © 2013 Elsevier Inc. All Rights Reserved. Source


Park J.-M.,CHA Cancer Institute | Jeong M.,CHA Cancer Institute | Kim E.-H.,CHA Cancer Institute | Han Y.-M.,CHA Cancer Institute | And 2 more authors.
BioMed Research International | Year: 2015

Omega-3 polyunsaturated fatty acids (n-3 PUFAs), commonly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been acknowledged as essential long-chain fatty acids imposing either optimal health promotion or the rescuing from chronic inflammatory diseases such as atherosclerosis, fatty liver, and various inflammatory gastrointestinal diseases. Recent studies dealing with EPA and DHA have sparked highest interests because detailed molecular mechanisms had been documented with the identification of its receptor, G protein coupled receptor, and GPR120. In this review article, we have described clear evidences showing that n-3 PUFAs could reduce various Helicobacter pylori- (H. pylori-) associated gastric diseases and extended to play even cancer preventive outcomes including H. pylori-associated gastric cancer by influencing multiple targets, including proliferation, survival, angiogenesis, inflammation, and metastasis. Since our previous studies strongly concluded that nonantimicrobial dietary approach for reducing inflammation, for instance, application of phytoceuticals, probiotics, natural products including Korean red ginseng, and walnut plentiful of n-3 PUFAs, might be prerequisite step for preventing H. pylori-associated gastric cancer as well as facilitating the rejuvenation of precancerous atrophic gastritis, these beneficial lipids can restore or modify inflammation-associated lipid distortion and correction of altered lipid rafts to send right signaling to maintain healthy stomach even after chronic H. pylori infection. © 2015 Jong-Min Park et al. Source

Discover hidden collaborations